TY - JOUR
AU - Drake, Thomas M.
AU - Fairfield, Cameron J.
AU - Pius, Riinu
AU - Knight, Stephen R.
AU - Norman, Lisa
AU - Girvan, Michelle
AU - Hardwick, Hayley E.
AU - Docherty, Annemarie B.
AU - Thwaites, Ryan S.
AU - Openshaw, Peter J.M.
AU - Baillie, J. Kenneth
AU - Harrison, Ewen M.
AU - Semple, Malcolm G.
AU - ISARIC4C Investigators
PY - 2021
DA - July
TI - Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort:a matched, prospective cohort study
JO - The Lancet Rheumatology
EP - E506
VL - 3
IS - 7
DO - https://doi.org/10.1016/S2665-9913(21)00104-1
AB - Background: Early in the pandemic it was suggested that pre-existing use of non-steroidal anti-inflammatory drugs (NSAIDs) could lead to increased disease severity in patients with COVID-19. NSAIDs are an important analgesic, particularly in those with rheumatological disease, and are widely available to the general public without prescription. Evidence from community studies, administrative data, and small studies of hospitalised patients suggest NSAIDs are not associated with poorer COVID-19 outcomes. We aimed to characterise the safety of NSAIDs and identify whether pre-existing NSAID use was associated with increased severity of COVID-19 disease.
PB - Elsevier
UR - https://www.research.ed.ac.uk/en/publications/8a59fb2f-7182-4d96-ae00-0b30d99f50c3
KW - Coronavirus (COVID-19)
KW - Hospital care
ER